Literature DB >> 28719997

The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison.

Sarah Martin1, Emma Trevor-Jones1, Sabyha Khan1, Keelan Shaw1, Deepti Marchment1, Anna Kulka1, Catherine E Ellis1, Rachel Burman1, Martin R Turner2, Liam Carroll3, Leah Mursaleen3, P Nigel Leigh3, Christopher E Shaw1, Neil Pearce4, Daniel Stahl1, Ammar Al-Chalabi1.   

Abstract

BACKGROUND: Care for people with amyotrophic lateral sclerosis (ALS) has altered at King's College Hospital over the last 20 years. The clinic has been a multidisciplinary, specialist, tertiary referral centre since 1995 with a large team with integrated palliative and respiratory care since 2006. We hypothesised that these changes would improve survival.
METHODS: In this retrospective observational study, patients diagnosed with El Escorial definite, probable and possible ALS between 1995-1998 and 2008-2011 were followed up. The primary outcome measure was a chi-square test for the proportion of each cohort surviving. Kaplan-Meier survival analysis and Cox multivariate regression were secondary analyses.
RESULTS: There was low reporting of some interventions. Five hundred and forty-seven people were included. Survival between the cohorts was significantly different (p = 0.022) with a higher proportion surviving during 2008-2011. Survival time was 21.6 (95% CI 19.2-24.0) months in the 2008-2011 cohort compared to 19.2 years (15.6-21.6) in the 1995-1998 cohort (log rank p = 0.018). Four hundred and ninety-three cases were included in the Cox regression. Diagnostic cohort was a significant predictor variable (HR 0.79 (0.64-0.97) p = 0.023).
CONCLUSIONS: These results support the hypothesis that integrated specialist clinics with multidisciplinary input improve survival in ALS.

Entities:  

Keywords:  Motor neuron disease; amyotrophic lateral sclerosis; care quality; multidisciplinary care; multidisciplinary team; survival

Mesh:

Year:  2017        PMID: 28719997     DOI: 10.1080/21678421.2017.1349151

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  6 in total

Review 1.  Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.

Authors:  Andrew P Tosolini; James N Sleigh
Journal:  Front Mol Neurosci       Date:  2017-12-07       Impact factor: 5.639

2.  CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.

Authors:  Paul Mehta; D Kevin Horton; Edward J Kasarskis; Ed Tessaro; M Shira Eisenberg; Susan Laird; John Iskander
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-12-22       Impact factor: 17.586

3.  Process evaluation and exploration of telehealth in motor neuron disease in a UK specialist centre.

Authors:  Esther Hobson; Wendy Baird; Mike Bradburn; Cindy Cooper; Susan Mawson; Ann Quinn; Pamela J Shaw; Theresa Walsh; Christopher J McDermott
Journal:  BMJ Open       Date:  2019-10-22       Impact factor: 2.692

4.  Using telehealth in motor neuron disease to increase access to specialist multidisciplinary care: a UK-based pilot and feasibility study.

Authors:  Esther V Hobson; Wendy O Baird; Mike Bradburn; Cindy Cooper; Susan Mawson; Ann Quinn; Pamela J Shaw; Theresa Walsh; Christopher J McDermott
Journal:  BMJ Open       Date:  2019-10-22       Impact factor: 2.692

5.  Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009-2011 and survival characteristics through 2015.

Authors:  Reshma Punjani; Laurie Wagner; Kevin Horton; Wendy Kaye
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-12-04       Impact factor: 4.092

Review 6.  Communication Matters-Pitfalls and Promise of Hightech Communication Devices in Palliative Care of Severely Physically Disabled Patients With Amyotrophic Lateral Sclerosis.

Authors:  Katharina Linse; Elisa Aust; Markus Joos; Andreas Hermann
Journal:  Front Neurol       Date:  2018-07-27       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.